<DOC>
	<DOCNO>NCT00448292</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled study ass safety efficacy PRX-00023 patient major depressive disorder .</brief_summary>
	<brief_title>A Efficacy Study PRX-00023 Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Patients major depressive disorder meet eligibility criterion randomly assign receive twice daily dos either placebo PRX-00023 . Study drug take approximately 9 week . Patients periodic office visit purpose monitor safety tolerability , well efficacy assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Naluzotan</mesh_term>
	<criteria>Key Diagnosis major depressive disorder Key Females pregnant nursing Electroconvulsive therapy within previous year Type 1 diabetes uncontrolled type 2 diabetes HIV , Hepatitis B Hepatitis C Use illegal drug , history drug abuse , and/or alcohol dependence Clinically significant abnormal lab result Other protocoldefined eligibility criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depression</keyword>
	<keyword>MDD</keyword>
</DOC>